Pentoxifylline, a drug with theological effects, decreases portal pressure in an experimental model of cirrhosis

European Journal of Gastroenterology and Hepatology

Volumn 9, Issue 1, 1997, Pages 27-31

  Sánchez, Susana ^a   Albornoz, Liliana ^a   Bandi, Juan Carlos ^a   Gerona, Solange ^a   Mastai, Ricardo ^a  

^a HOSPITAL ITALIANO DE BUENOS AIRES   (Argentina)

Author keywords

Blood viscosity; Cirrhosis; Pentoxifylline; Portal hypertension; Portal pressure

Indexed keywords

ANTITHROMBOCYTIC AGENT; PENTOXIFYLLINE; RADIOACTIVE MICROSPHERE; VASODILATOR AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD VISCOSITY; CONTROLLED STUDY; FILTRATION; HEART INDEX; HEMODYNAMICS; INTRAVENOUS DRUG ADMINISTRATION; LIVER CIRRHOSIS; MALE; MEAN ARTERIAL PRESSURE; NONHUMAN; PORTAL VEIN BLOOD PRESSURE; PRIORITY JOURNAL; RAT; SHEAR RATE; SPLANCHNIC BLOOD FLOW; VISCOMETER; ANIMAL; CHOLESTASIS; COMPARATIVE STUDY; DISEASE MODEL; DOUBLE BLIND PROCEDURE; DRUG EFFECT; EXPERIMENTAL LIVER CIRRHOSIS; HEART OUTPUT; PATHOPHYSIOLOGY; PORTAL HYPERTENSION; WISTAR RAT;

ANIMALS; BLOOD VISCOSITY; CARDIAC OUTPUT; CHOLESTASIS; DISEASE MODELS, ANIMAL; DOUBLE-BLIND METHOD; HYPERTENSION, PORTAL; INFUSIONS, INTRAVENOUS; LIVER CIRRHOSIS, EXPERIMENTAL; MALE; PENTOXIFYLLINE; PORTAL PRESSURE; RATS; RATS, WISTAR; VASODILATOR AGENTS;

EID: 0030614470     PISSN: 0954691X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042737-199701000-00009     Document Type: Article

References (26)

1. Groszmann RJ, Blei A, Atterbury C: Portal hypertension. In The Liver Biology and Pathology. Edited by Arias I, Jakoby W, Popper H, Schachner D, Shafritz D. Raven Press; 1988:1147-1159.
2. Lebrec D, Hillon P, Muñoz C, Goldfarb G, Nouel O, Benhamou JP: The effect of propranolol on portal hypertension in patients with cirrhosis: a hemodynamic study. Hepatology 1982, 2:523-527.
3. Kroeger IR, Groszmann RJ: Increased portal venous resistance hinders portal pressure reduction during the administration of beta adrenergic blocking agents in a portal hypertensive model. Hepatology 1985, 5:97-101.
4. Bosch J: Effect of pharmacological agents on portal hypertension: a hemodynamic appraisal. Clin Gastroenterol 1985, 14:169-183.
5. Mastai R, Giroux L, Semret M, Huet PM: Ritanserin decreases portal pressure in conscious and unrestrained cirrhotic rats. Gastroenterology 1990, 98:141-145.
6. Ward A, Clissold S: Pentoxifylline. A review of its pharmacodynamic and pharmacokinetic properties and its therapeutic efficacy. Drugs 1987, 34:50-97.
7. Lee SS, Girod C, Braillon A, Hadengue A, Lebrec D: Hemodynamic characterization of chronic bile-duct ligated rats: effects of pentobarbital sodium. Am J Physiol 1986, 251:G176-G180.
8. Bull B, Chien S, Dormandy J, Kiesewetter H, Lewis SM, Lowe GDO, et al.: Guidelines for measurement of blood viscosity and erythrocyte deformability. Clin Hemorheol 1986, 6:439-453.
9. Reid H, Barnes P, Lock J, Dormandy A: A sample method for measuring erythrocyte deformability. J Clin Pathol 1976, 29:855-888.
10. Waxman K, Holness R, Tominaga G, Oslund S, Pinderski L, Soliman MH: Pentoxifylline improves tissue oxygenation after hemorrhagic shock. Surgery 1987, 102(2):358-361.
11. Beermann B, Ings R, Mansby J, Chamberbin J, McDonald A: Kinetics of intravenous and oral pentoxifylline in healthy subjects. Clin Pharmacol Ther 1985, 37(1):25-28.
12. Blei A: Vasodilatory therapy of portal hypertension: focus on the liver. Hepatology 1989, 9:896-899.
13. 2 serotoninergic antagonist, on portal pressure and splanchnic hemodynamics in portal hypertensive rats. Hepatology 1991, 14:1174-1178.
14. Reichen J, Le M: Verapamil favorably influences hepatic microvascular exchange and function in rats with cirrhosis of the liver. J Clin Invest 1986, 78:448-455.
15. Marteau P, Ballet F, Chazouilleres O, Chretien Y, Rey C, Petit D, et al.: Effect of vasodilators on hepatic microcirculation in cirrhosis: a study in the isolated perfused rat liver. Hepatology 1989, 9:820-823.
16. Dagenais M, Pomier-Layrargues G, Rocheleau B, Giroux L, Huet PM: Systemic and splanchnic hemodynamic effects of pentoxifylline in rats with portal hypertension. Clin Sci 1992, 83:41-45.
17. Hoeffner B, Arrhus L, Katusic Z, Vanhoutte P: Pharmacology of pentoxifylline in isolated canine arteries and veins. J Cardiovasc Pharmacol 1989, 97:337-345.
18. Sinzinger H: Pentoxifylline enhances formation of prostacyclin from rat vascular and renal tissue. Prostaglandins Leukotrienes Med 1983, 12:217-226.
19. Grange J, Jaillom P, Woblinski B, Fancherre V, Ballet F, Vasmant D, et al.: La pentoxifylline: un traitement potentiel des cirrhoses avec hypertension portale? Gastroenterol Clin Biol 1987, 11:161.
20. Feu F, García Pagán JC, Ruiz del Arbol L, Cirrera J, Pizcueta P, Bosch J, et al.: Lack of effect of pentoxifylline on portal pressure and hepatic hemodynamics in cirrhosis. J Hepatol 1990, S87.
21. Kramer J, Swislocki N: Effect of pentoxifylline on membrane protein phosphorilation in rat erythrocyte. Vasc Med 1983, 1:159-174.
22. Owen J, Bruckdorfer R, Day R, McIntyre N: Decreased erythrocyte membrane fluidity and altered lipid composition in human liver disease. J Lipid Res 1982, 23:124-132.
23. Cooper R: Hemolytic syndromes and red cell membrane abnormalities in liver disease. Semin Hematol 1980, 17:103-111.
24. Levy R, Schlaeffer F, Keynan A, Nagauker O, Yaari A, Sikuler E: Increased neutrophil function induced by bile duct ligation in a rat model. Hepatology 1993, 17(5):908-914.
25. Schmalzer EA, Chien S: Filterability of subpopulations of leukocytes: effect of pentoxifylline. Blood 1984, 64(2):542-546.
26. Bittecher DC, Keller H, Maly F, Reinhart WH: The effect of endotoxin and tumor necrosis factor on erythrocyte and leukocyte deformability in vitro. Br J Haematol 1993, 83:130-137.